在心力衰竭中的健康公平
Aishwarya Vijay1, Clyde W Yancy1
1Department of Internal Medicine, Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States of America.
Progress in cardiovascular diseases
|January 12, 2024
概括
在心力衰竭 (HF) 治疗中实现健康平等至关重要. 解决指南导向医学疗法 (GDMT) 的差异,确保所有降低射出分数 (HFrEF) 的患者都能从先进的HF护理中受益.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 健康 公平 卫生 公平
背景情况:
- 低射率心力衰竭 (HFrEF) 治疗已经在以证据为基础的疗法方面取得了显著进展.
- HFrEF治疗的"四大支柱"包括β抑制剂,RAAS抑制剂,MRA和SGLT2抑制剂,改善生存和生活质量.
- 尽管已证明有好处,但对HFrEF的指南导向医学疗法 (GDMT) 尚未得到充分利用,特别是在少数群体中,造成了显著的健康差异.
研究的目的:
- 在心力衰竭护理中强调健康平等和健康公平之间的差异.
- 在HFrEF讨论公平待遇的必要性,确保所有人从治疗进步中受益.
- 提出减少和消除HFrEF管理中的健康差异的策略.
主要方法:
- 对HFrEF目前基于证据的医学疗法的审查.
- 在GDMT的应用中分析健康差异.
- 在HF讨论社会经济决定因素和种族主义作为对公共健康的威胁.
- 建议将伦理原则与GDMT相结合,以个性化HFrEF治疗.
主要成果:
- 在脆弱人群中使用有效的HFrEF治疗方法存在显著差异.
- 社会经济因素和种族主义被认为是导致这些健康不平等的关键决定因素.
- 2022年AHA/ACC/HFSA指南强调解决高频差异.
结论:
- 在心力衰竭治疗中实现真正的公平需要解决系统性差异.
- 个性化治疗策略,将伦理考虑与GDMT整合起来,对于公平的HFrEF护理至关重要.
- 消除HFrEF治疗中的差异至关重要,以确保所有患者获得最佳的心血管益处.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591